Boston, MA, 03/11/2014 – IGI Laboratories, Inc. (NYSEMKT:IG), a small-cap manufacturer, developer and marketer of generic topical pharma products, reached a high of over 11% in the last trading session. After delivering quite decent returns in its last quarter, the company’s management is growing its pipeline phenomenally, as nearly 10 more ANDA filings are expected this year. This is in addition to the 14 ANDAs already filed as of now. IGI Laboratories, Inc. (NYSEMKT:IG) was reported to have presented at the 26th Annual ROTH conference yesterday.
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), a bio-pharma company engaged in the advancement and marketing of new first-in-class cancer therapies, which aim at addressing treatment resistance in cancer patients, has been moving high. The bio-pharma company recently received a ‘Buy’ upgrade from the analyst at CRT capital, which as assigned a price target of $20 per share to it. The analyst at CRT mentioned in the research report that the rating comes in light of the expectation of positive results from its Phase III Synergy clinical trial in castrate resistant prostate cancer. Moreover, the analyst target it to complete FDA filing for the same in the second half of 2014.
In a sudden reversal of internal policy, the U.S. largest bank Wells Fargo & Co (NYSE:WFC) is said to have lifted the ban on its staff over making loans on peer-to-peer platforms. The bank said that as per its latest review of the “P2P’ market, it came to a conclusion that the loans made by its employees on this platform is consistent with its code of ethics. Earlier, the bank had imposed ban on such loans made to P2P platforms, citing conflict of interest, which signalled the growing tension between the P2P platforms and the banks. The step drew mixed reactions from the analyst fraternity, where some favored the stance, but others condemned the move, quoting the rise of P2P as a mainstream rival to banks.